ReviewCurrent opinion in microbiology2017
The emerging metabolic view of Clostridium difficile pathogenesis.
Review in Current opinion in microbiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed.
- Metabolic Syndrome Is Associated With Increased Risk ofOpen forum infectious diseases · 2026Article
- Lipidomics, Microbiota, and IntestinalInternational journal of molecular sciences · 2025Review
- A data-driven modeling framework for mapping genotypes to synthetic microbial community functions.bioRxiv : the preprint server for biology · 2025Article
- Unraveling Cecal Alterations inJournal of proteome research · 2024Article
- Fecal Microbiota Transplantation for RecurrentMicroorganisms · 2024Article
- Article
- Eight Unexpected Selenoprotein Families in Organometallic Biochemistry in Clostridium difficile, in ABC Transport, and in Methylmercury Biosynthesis.Journal of bacteriology · 2023Article
- Antibacterial Activity of Ebselen.International journal of molecular sciences · 2023Review
- Computational approaches to understanding Clostridioides difficile metabolism and virulence.Current opinion in microbiology · 2022Review
- Multi-omics investigation ofeLife · 2022Article
- Children gut microbiota exhibits a different composition and metabolic profile afterFrontiers in microbiology · 2022Article
- The impact of dietary fibers onFrontiers in cellular and infection microbiology · 2022Article
- Discovery of a novel natural product inhibitor of Clostridioides difficile with potent activity in vitro and in vivo.PloS one · 2022Article
- Microbiome Management for the 21st Century and Beyond.mSystems · 2021Article
- Mucin-Degrading Microbes Release Monosaccharides That ChemoattractACS infectious diseases · 2021Article
- Article
- Computational modeling of the gut microbiota reveals putative metabolic mechanisms of recurrent Clostridioides difficile infection.PLoS computational biology · 2021Article
- Invisible steps for a global endemy: molecular strategies adopted byTherapeutic advances in gastroenterology · 2021Review
- Diverse Energy-Conserving Pathways in Clostridium difficile: Growth in the Absence of Amino Acid Stickland Acceptors and the Role of the Wood-Ljungdahl Pathway.Journal of bacteriology · 2020Article
- The cytotoxic synergy between Clostridioides difficile toxin B and proinflammatory cytokines: an unholy alliance favoring the onset of Clostridioides difficile infection and relapses.MicrobiologyOpen · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
It is widely accepted that Clostridium difficile exploits dysbiosis and leverages inflammation to thrive in the gut environment, where it can asymptomatically colonize humans or cause a toxin-mediated disease ranging in severity from frequent watery diarrhea to pseudomembranous colitis or toxic megacolon. Here, we synthesize recent findings from the gut microbiota and enteric pathogenesis fields to inform the next steps toward a better understanding of C. difficile infection (CDI). In this review, we present a model in which the lifestyle of C. difficile is dictated by the metabolic state of the distal gut ecosystem. Contributions by C. difficile (specifically the production and action of the large glycosylating toxins TcdA and TcdB), the microbiota, and the host dictate whether the gut environment is supportive to the pathogen. Mechanistic, metabolic pathway-focused approaches encompassing the roles of all of these players are helping to elucidate the molecular ecology of the distal gut underlying a diseased or healthy ecosystem. A new generation of therapeutic strategies that are more targeted (and palatable) than fecal microbiota transplants or broad-spectrum antibiotics will be fueled by insight into the interspecies (host-microbe and microbe-microbe) interactions that differentiate healthy from pathogen-infested microbiotas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.